Entering text into the input field will update the search result below

CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study

  • CEL-SCI Corporation (NYSE:CVM) announces that the Independent Data Monitoring Committee (IDMC) has completed its review for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection). The study enrolled 928 patients.
  • The IDMC saw no evidence of any significant safety questions and recommended continuing the study.
  • Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval.
  • Shares are up 4% premarket on modest volume.

Recommended For You

About CVM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CVM--
CEL-SCI Corporation